What question did this study set out to answer?

This research aims to evaluate first-line therapies for mantle cell lymphoma using Bruton’s tyrosine kinase inhibitors.

August 9, 2026Open Access

First-Line Bruton’s Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma

View Full Paper

Ask AI

Bookmark

Authors

Randomized trials examine first-line therapy options for mantle cell lymphoma, suggesting tailored approaches for patient care.

This research aims to evaluate first-line therapies for mantle cell lymphoma using Bruton’s tyrosine kinase inhibitors.
Reviewed recent phase II and phase III trials on cBTKi combinations.
Discussed treatment selection criteria including patient characteristics and MCL biology.
Presented three patient cases to illustrate therapy selection among new regimens.
Novel cBTKi combinations show significant activity in MCL treatment.
Flexibility in treatment decision-making is needed based on individual patient factors.
Identified gaps in evidence regarding long-term efficacy and safety of these regimens.

Puckrin et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark